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Abstract 
Background: In critically ill patients, tigecycline (TGC) remains an important therapeutic option due to its efficacy 
against multiresistant Gram-positive and Gram-negative bacteria. TGC is metabolized and eliminated predominantly 
by the liver. Critical illness-induced liver failure may have a profound impact on the pharmacokinetic of TGC. In the 
present study, we aimed to establish a link between the degree of liver dysfunction and TGC plasma concentration 
using the novel maximum liver function capacity (LiMAx) test, as a dynamic liver function test.
Materials/methods: The prospective study included 33 patients from a surgical ICU with the clinical indication for 
antibiotic therapy with TGC. The patients received 100 mg loading dose of TGC followed by intermittent standard 
doses of 50 mg q12. Blood samples for TGC plasma concentration were collected at 0.3, 2, 5, 8 and 11.5 h in a steady-
state condition after at least 36 h post-standard dosage. The results were analyzed by means of a high-performance 
liquid chromatography (HPLC) method. Within the same day, the LiMAx test was carried out and routine blood param-
eters were measured.
Results: Peak plasma concentrations of TGC were significantly higher in patients with severe liver failure 
(LiMAx < 100 µg/kg/h) when compared to patients with normal liver function (LiMAx > 300 µg/kg/h). The pharmacoki-
netic curves revealed higher values in severe liver failure at any measured point. Moreover, LiMAx and total bilirubin 
were the only liver-related parameters that correlated with TGC Cmax.
Conclusions: The present study demonstrates a high variability of TGC plasma concentrations in critically ill patients. 
The results show a significant correlation between the degree of liver dysfunction, measured by the LiMAx test, and 
TGC Cmax. LiMAx test may be a helpful tool beyond others for adjusting the required dosage of hepatic metabolized 
antibiotics in critically ill patients.
Trial registry DRKS—German clinical trials register; Trial registration number: DRKS00008888; Date of registration: 07-17-
2015; Date of enrolment of the first participant to the trial: 12-10-2015
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Background
Patients in the intensive care unit (ICU) are prone to 
develop bacterial infections, followed by an indication 
for antibiotic therapy. Due to altered pathophysiology in 
critically ill patients, finding the appropriate antimicro-
bial dosing is challenging with the risk of a drug over- or 
under-dosing, which may result in poor clinical outcome 
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[1]. Tigecycline (TGC) is a glycylcycline antimicrobial 
agent, approved in 2005 by the United States Food and 
Drug Administration (FDA) for the treatment of compli-
cated intra-abdominal and skin-structure infections [2–
4]. It shows an expanded broad-spectrum activity against 
important and relevant sensible and multiresistant 
Gram-positive and Gram-negative bacteria such as 
(methicillin-resistant) Staphylococcus aureus (MRSA), 
(vancomycin-resistant) Enterococci (VRE) and (extended-
spectrum β-lactamase-producing) Enterobacteriaceae 
(ESBL) [5]. TGC is considered as a last resort option 
for difficult-to-treat infections. However, data regarding 
suboptimal TGC dosing indicate a correlation with an 
increased risk of death [6]. Consequently, several clinical 
studies are heading towards a high-dose regimen of TGC 
therapy as an approach to increase its efficacy [6, 7].
On the other hand, understanding of the altered renal 
or hepatic function can be an alternative approach in 
adjusting antibiotic dosing. For instance, hepatic func-
tion plays a role in the clearance of TGC, as almost 60% 
of TGC is eliminated primarily via biliary excretion and 
approximately 20% is metabolized by the liver [6, 8, 9]. 
Due to a lack of reliable liver function tests, it is difficult 
to obtain sufficient data guiding clinicians in TGC dose 
adjustment in critically ill patients with liver dysfunction.
The maximal liver function capacity (LiMAx) test has 
been recently introduced as a non-invasive diagnostic 
tool for determining acute liver failure in the intensive 
care medicine [10]. It determines the enzyme activity of 
the liver based on a non-invasive breath test. Concern-
ing antibiotic dosing of non-renal eliminated drugs, one 
recent study demonstrated a correlation between LiMAx 
and the pharmacokinetics (PK) of linezolid [11].
In our study, we aimed to examine the impact of liver 
dysfunction on the PK of TGC in critically ill patients 
using the novel LiMAx test.
Methods
Patients and study design
This current study was approved by the ethics review 
board of the Charité medical faculty (EA4/022/13) in 
accordance with the provisions of the declaration of Hel-
sinki. Prior to study inclusion, written informed consent 
was obtained from all participants or their responsible 
legal representatives.
Patients were recruited from the surgical ICU of the 
Charité University Hospital, Berlin, Germany. Inclusion 
criteria were a medical indication for intravenous anti-
infective therapy with TGC and an age between 18 and 
99 years. Exclusion criteria were an allergy against TGC 
or methacetin, co-medication with substances metabo-
lized by cytochrome P450 1A2 or with substances affect-
ing the clearance of TGC or missing informed consent. 
Microbiological samples were obtained from any sus-
pected source of infection, as well as from blood (in 
duplicate for anaerobic and aerobic testing) prior to the 
first TGC dosages. The samples were sent to a central 
laboratory for verification of the causative pathogen, 
minimal inhibitory concentrations (MIC) breakpoints 
determination and storage. MIC values were determined 
by broth microdilution testing (BMT). According to the 
current guidelines, patients with septic shock or detec-
tion of TGC-resistant pathogens in the microbiological 
samples were treated with TGC only in combination with 
other broad-spectrum antibiotics [12].
Patients received an initial dose of 100  mg of TGC 
in a 30  min infusion, followed by multiple doses of 
50 mg/30 min q12. In order to measure the plasma con-
centrations of TGC in a steady-state condition, meas-
urement and probe sampling were carried out at least 
36 h after the first dosage of TGC. On the same day, the 
LiMAx test was performed according to recent publica-
tions and serum samples for static liver function param-
eters and routine blood parameters were taken [11, 13]. 
Static liver function parameters included aspartate ami-
notransferase (AST), alanine aminotransferase (ALT), 
gamma-glutamyl transferase (GGT), pseudocholinest-
erase (PCHE), glutamate dehydrogenase (GLDH), alka-
line phosphatase (ALP), total bilirubin, lactate, platelets 
count and international normalized ratio (INR). For 
pharmacokinetic analysis of TGC, 5  mL of heparinized 
blood samples were collected at 0.3, 2, 5, 8 and 11.5  h 
after the end of TGC infusion. Within 1  h after collec-
tion, blood samples were centrifuged at 4000  rpm for 
5 min and plasma aliquots were stored at − 80 °C. Plasma 
TGC concentrations were determined using a previ-
ously described high-performance liquid chromatog-
raphy method (HPLC) [14]. In addition, we conducted 
the model for end-stage liver disease (MELD score). The 
severity of illness was defined using the Acute Physiology 
and Chronic Health Evaluation (APACHE II) score, the 
Sepsis Organ Failure Assessment (SOFA) score and the 
Simplified Acute Physiology Score II (SAPS II).
After assessing the pharmacokinetics of TGC with 
the identified bacteria associated with the infection, 
patients were divided into three groups depending on 
their LiMAx value on the day of measurement accord-
ing to previously published data [10]. Group A included 
patients with LiMAx values < 100  μg/kg/h (severe liver 
failure), group B patients with LiMAx values between 
100 and 300  μg/kg/h (moderate liver failure) and group 
C patients with LiMAx values > 300 μg/kg/h (normal liver 
function). To correlate TGC serum levels with liver func-
tion, we compared the three different groups focussing 
mainly on Group A and C. To identify factors predicting 
TGC Cmax, a linear multivariate regression analysis was 
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conducted including parameters that were found differ-
ent between group A and C.
Statistical analysis
Continuous variables were shown as median and inter-
quartile range; meanwhile, the categorical variables were 
presented in frequencies. The suitable statistical test was 
conducted depending on the values’ distribution of each 
variable using Kolmogorov–Smirnov test in combination 
with the Shapiro–Wilk test. Comparisons in normally 
distributed variables were performed using the Mann–
Whitney U test. Not normally distributed variables were 
tested using the independent t test for non-connected 
samples. A p-value of < 0.05 was considered statistically 
significant.
Multivariate linear regression was performed to iden-
tify parameters related to liver function predicting TGC 
Cmax variability. These parameters were included in the 
final regression analysis after meeting the assumption of 
collinearity. This was tested using Pearson’s Chi-squared 
test to examine the correlation between liver function 
parameters with each other. The assumption was verified 
by observing the variance inflation factor and tolerance 
in the final regression analysis. Moreover, the correla-
tion between LiMAx and TGC PK parameters were ana-
lyzed using simple linear regression. The log-trapezoidal 
rule was used to compute the area under the concentra-
tion–time curve (AUC) from 0 to 12 h for the mean con-
centration–time data in plasma. Statistical analysis was 
carried out using SPSS Statistics 22 (SPSS Inc., Chicago, 
IL, USA).
Results
Demographic and characteristics of patient groups
A total of 33 patients were included. These patients were 
divided into the three LiMAx groups as follows: (A) 
LiMAx < 100  μg/kg/h (n = 5); (B) LiMAx 100–300  μg/
kg/h (n = 21) and (C) LiMAx > 300  μg/kg/h (n = 7). In 
all patients, the indication of TGC therapy was compli-
cated intra-abdominal sepsis. Enterococcus faecium was 
the most commonly observed pathogen (33.3%) in the 
microbiological samples with a MIC value of 0.12 mg/L 
(Table  1). Forty-two percent (n = 14) of the causative 
organisms were Gram-negative with a MIC value of 
0.5  mg/L (Table  1). Comparisons of the baseline char-
acteristics between groups A and C revealed significant 
differences in the SOFA score (p = 0.019) and the BMI 
(p = 0.018) (Table 2).
Pharmacokinetics of TGC 
The mean TGC concentrations in plasma-versus-time 
profiles in the whole population are shown in Fig.  1. 
Mean plasma concentrations of TGC showed peak levels 
(Cmax = 0.805  mg/L) 0.3  h after TGC bolus administra-
tion, followed by a decrease until reaching a trough level 
(Cmin = 0.377 mg/L) 0.5 h before the next TGC bolus. A 
statistical summary of pharmacokinetic and pharma-
codynamic exposure variables of TGC is presented in 
Table  3. For the Gram-positive bacteria, 99.6% of TGC 
dose interval was above MIC < 0.12 mg/L without MRSA, 
where 99.1% of the TGC was above MIC < 0.25 mg/L with 
MRSA. For the Gram-negative bacteria 35% of TGC dos-
ing was above the corresponding MIC values.
TGC mean plasma concentration curves between 
groups A–C are shown in Fig.  2. The total extension of 
Cmax ranged from 0.441 to 1.774 mg/L. The highest mean 
values of Cmax were observed in group A and lowest in 
group C (1.135  mg/L vs. 0.581  mg/L, p = 0.004). Group 
A presented TGC PK curves with the highest and group 
C with the lowest mean values. Group B showed TGC 
mean values in between groups A and C. Mean val-
ues of groups A and C were significantly different at all 
Table 1 Pathogens associated with infections caused in the study population
MRSA: methicillin-resistant Staphylococcus aureus; VRE: vancomycin-resistant Enterococci; ESBL: extended betalactamase producing Gram-negative bacteria; MIC: 
minimum inhibitory concentration
Total (n = 33) Group A (n = 5) Group B (n = 21) Group C (n = 7) MIC breakpoints 
(mg/L)
Microbiological isolate, n (%)
 Enterococcus avium 1 (3) 0 1 (4.8) 0 0.12
 Enterococcus faecalis 3 (9.1) 2 (40) 1 (4.8) 0 0.12
 Enterococcus faecium 11 (33.3) 4 (80) 7 (33.3) 0 0.12
 Escherichia coli 4 (12.1) 2 (40) 2 (9.5) 0 0.5
 MRSA 1 (3) 0 0 1 (14.3) 0.25
 Staphylococcus epider-
midis
2 (6.1) 0 3 (14.3) 1 (14.3) 0.12
 VRE 9 (27.3) 2 (40) 3 (14.3) 4 (57.1) 0.12
 ESBL 10 (30.3) 3 (60) 4 (19) 3 (42.9) 0.5
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time-dependent measuring points (0.3  h: p = 0.004; 2  h: 
p = 0.02; 5 h: p = 0.02; 8 h: p = 0.004; 11.5 h: p = 0.011). In 
view of the pharmacodynamics of TGC, the AUC/MIC 
in group A patients was higher compared to patients in 
group C against both Gram-negative and Gram-positive 
bacteria (68.383 vs. 25.827 for Gram-positive bacteria 
Table 2 Baseline characteristics
Data are presented as median and interquartile range (25th to 75th percentile) or frequencies
BMI: body mass index; WBC: white blood cell count; CRP: C-reactive protein; INR: international normalized ratio; SOFA: Sequential Organ Failure Assessment; SAPS: 
Simplified Acute Physiology Score; APACHE II: Acute Physiology and Chronic Health Evaluation; p value: comparison between group A and D: aIndependent t test, 
bMann–Whitney U test, cFisher’s exact test
Total Group A Group B Group C pa,b,c
Patients (n) 33 5 21 7
Age (year) 63 (54–73) 59 (54–77) 65 (55–73) 59 (54–68) 0.456a
Gender (m/f ) 20/13 3/2 14/7 ¾ 0.812c
BMI (kg/m2) 26.4 (22.6–31.2) 22.5 (18.3–22.7) 27.7 (24.4–31.1) 31.3 (24.5–46.4) 0.018b
WBC (/nL) 17 (13–22) 26 (25–34) 14 (10–21) 15 (11–35) 0.190b
CRP (mmol/L) 124.2 (78.3–217.3) 88.8 (61.1–197.8) 135 (106.9–176.8) 114.3 (42.2–210.8) 0.899a
INR 1.38 (1.24–1.54) 1.28 (1.24–1.54) 1.39 (1.28–1.56) 1.34 (1.19–1.98) 0.584a
Lactate (mg/dL) 15 (12–27) 30 (21–55) 15 (11–21) 15 (13–26) 0.114b
Platelets count (/nL) 182 (104–374) 136 (68–287) 171 (88–310) 335 (187–444) 0.127a
Albumin (g/L) 22.6 (19.6–25.03) 22.9 (16.8–29.2) 22.7 (18–25.4) 24 (16.8–25.2) 0.766a
Creatinine clearance (mL/min) 32 (20–64) 29 (0–75) 32 (21–57) 32 (25–89) 0.606a
SOFA score 9 (5–11) 12 (11–16) 9 (5–11) 8 (4–10) 0.017a
SAPSII score 55 (41–72) 57 (51–65) 59 (39–71) 55 (35–68) 0.547a
APACHE II score 23 (18–30) 27 (21–34) 25 (15–28) 28 (19–30) 0.698a
Duration of therapy (days) 8 (6–12) 7 (4–9) 9 (7–14) 6 (5–12) 0.857b
Fig. 1 Mean TGC plasma concentrations depending in the study population. Data are presented as mean ± standard deviation
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without MRSA and 16.412 vs. 7.748 for Gram-negative 
bacteria, p < 0.05).
Hepatic dysfunction
The LiMAx test showed significantly lower values in 
group A compared to group C (71  μg/kg/h vs. 438  μg/
kg/h, p < 0.001). Static liver function tests demonstrated 
significantly higher parameters for lactate (27  mmol/L 
vs. 12 mmol/L, p = 0.001) and INR (2.1 vs. 1.3, p = 0.017) 
in group A. Platelet counts (60/nL vs. 312/nL, p = 0.017) 
and ALP (105  IU/L vs. 271  IU/L, p = 0.017) revealed 
lower values in group A. Other parameters such as 
MELD score, total bilirubin, AST, ALT and GGT showed 
no significant difference within the groups (Table 4).
Multivariate analysis
LiMAx and total bilirubin were the only parameters pre-
dicting TGC Cmax. LiMAx was negatively correlated with 
TGC Cmax, indicating higher TGC plasma levels when 
LiMAx values were low. Total bilirubin was positively 
correlated with TGC Cmax. Other variables (lactate, INR 
and MELD score) failed in correlating with TGC Cmax. 
This multiple regression model accounts for about 40% 
of TGC Cmax variance with F (3.30) = 8.539 (p < 0.001) 
(Table 5).
A demonstrated scatter plot revealed a strong negative 
linear correlation between LiMAx and TGC PK param-
eters. Simple linear regression showed a significant cor-
relation between LiMAx and TGC Cmax (p < 0.001) and 
between LiMAx and TGC AUC 0–12. The R2 value for both 
was almost similar reaching 0.195, indicating that nearly 
20% of the variation in TGC Cmax and TGC AUC 0–12 may 
Table 3 Summary of pharmacokinetic and pharmacodynamic parameters of TGC 
AUC: area under the concentration–time curve over 12 h; MIC: minimum inhibitory concentration
Measure Cmax (mg/L) AUC (mg h/L) MIC (mg/L) AUC/MIC
0.805 5596 Gram positive without 
MRSA
0.12 46.63
Gram negative 0.5 11.192
Fig. 2 Mean TGC plasma concentrations depending on the degree of liver failure. Data are presented as mean ± standard deviation
Page 6 of 9Alraish et al. Ann. Intensive Care          (2020) 10:106 
be explained by quantifying liver function using only the 
LiMAx test. The scatterplot of standardized predicted 
values versus standardized residuals indicated that the 
data met the assumptions of homogeneity of variance 
and linearity. The residuals were approximately distrib-
uted normally (Fig. 3).
Discussion
The present study investigated the effect of liver failure on 
TGC PK for the first time. Based on recently conducted 
trials, we established a novel strategy using the LiMAx 
test for quantifying hepatic dysfunction [10, 15, 16]. Our 
findings showed a significant increase in TGC PK curves 
in patients with strong hepatic dysfunction (group A), 
compared to patients with normal liver function (group 
C). The results of the multivariate analysis confirmed this 
effect. Regarding liver function, only LiMAx and total bil-
irubin revealed a significant impact on TGC Cmax.
TGC Cmax in our patient groups ranged from 0.441 
to 1.774  mg/L. They were within the range to those 
Table 4 Comparison of static and dynamic liver parameters
Data are presented as median and interquartile range (25th to 75th percentile)
LiMAx: maximum liver function capacity; INR: international normalized ratio; AST: aspartate aminotransferase; ALT: alanine aminotransferase; GGT: gamma-glutamyl 
transferase; ALP: alkaline phosphatase; MELD: model for end-stage liver disease
a Independent t test
b Mann–Whitney U test
Group A Group C pa,b
LiMAx (μg/kg/h) 71 (37–88) 438 (330–456) < 0.001b
Lactate (mmol/L) 27 (24–30) 12 (9–14) 0.001a
INR 2.1 (1.5–2.7) 1.3 (1.3–1.4) 0.017a
Total bilirubin (mmol/L) 2.8 (1.5–5.6) 1.6 (0.6–2.2) 0.209a
Platelet counts (/nL) 60 (46–83) 312 (177–462) 0.017a
AST (IU/L) 28 (24–56) 59 (43–74) 0.097a
ALT (IU/L) 13 (12–39) 52 (33–94) 0.053a
GGT (IU/L) 67 (59–76) 202 (84–485) 0.051a
ALP (IU/L) 105 (83–152) 271 (143–381) 0.017a
MELD score 18 (16–36) 14 (11–23) 0.201b
Table 5 Multiple linear regression model: co-factors 
predicting TGC Cmax
LiMAx value (maximum liver function capacity), total bilirubin, Lactate, MELD 
score (model for end-stage liver disease) and INR (international normalized ratio)
Beta p-value
Constant < 0.001
Total bilirubin (mg/dL) 0.495 0.001
LiMAx value (µk/kg/h) − 0.293 0.044
Lactate – 0.336
MELD score – 0.211
INR – 0.558
Fig. 3 Relationship between LiMAx and TGC PK, AUC (a) and Cmax (b). Cmax: TGC maximum plasma concentration; AUC: area under the curve
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determined in previous clinical trials with healthy vol-
unteers [3, 17]. However, extrapolating data of healthy 
subjects into critically ill patients is a challenge due to 
altered pathophysiology in this specific patient popu-
lation. Particularly, the role of liver dysfunction is not 
sufficiently described, so far [1]. Moreover, limited data 
are published, illuminating the pharmacokinetic of 
TGC in critically ill patients.
The LiMAx test has previously shown promising 
results in quantifying hepatic function in sepsis. The 
investigators concluded that LiMAx was a reliable 
diagnostic tool for identifying liver failure in critically 
ill patients [10]. In another study, LiMAx explained a 
reasonable part of the linezolid PK variability of criti-
cally ill patients regarding the degree of liver failure. 
The authors demonstrated a strong association between 
LiMAx and non-renal clearance of linezolid by reduc-
ing the interindividual variability from 46.6 to 33.6%. 
LiMAx was superior to other markers of organ fail-
ure such as creatinine clearance (CLCr), thrombocyte 
count, total bilirubin and GGT even though an oppor-
tunistic probe sampling with linezolid trough levels 
was chosen in this work [11]. The results of the pre-
sent study with a more sophisticated strategy reflecting 
the PK of TGC demonstrate that LiMAx may provide 
an adequate diagnostic tool for predicting high TGC 
plasma levels in patients with hepatic dysfunction. Par-
ticularly, the LiMAx results < 100  µg/kg/h should lead 
to increased attention from the physicians. In  vitro, 
data of TGC revealed a protein binding of about 
50–70% [18]. A low protein-binding of TGC yields a 
high volume distribution in the different body compart-
ments and may lead to an imprecise interpretation of 
TGC plasma levels. Hence, a dosage algorithm based 
on the therapeutic drug monitoring of the TGC plasma 
level may be challenging to establish. Studies investi-
gating TGC levels in other human body fluids such as 
bile or ascites are further required.
LiMax also provided some superior insights into the 
dosage regimes used across the norm. Since December 
2018, EUCAST recommends a 200  mg loading dose of 
TGC followed by 100  mg steady-state dosage in treat-
ing critically ill patients infected with pathogens resist-
ant to all other classes of antimicrobials [19]. In our 
clinical study, a standard dosage, 100  mg loading dose 
of TGC followed by 50 mg steady-state dosage has been 
used. We observed, in Gram-positive bacteria, that criti-
cally ill patients in group A (68.383) had a significantly 
higher AUC above the MIC values than patients in group 
C (25.827). Similarly, in Gram-negative bacteria, group 
A (16.412) had a higher AUC above the MIC values 
than patients in group C (7.748). In such circumstances, 
EUCAST recommended dosage could lead to an increase 
in the risk of developing resistance towards TGC.
Another dynamic liver function test is the ICG-PDR, 
which is more widely used in clinical settings than the 
LiMAx test. Several authors investigated ICG-PDR in 
different conditions. The majority of authors came to the 
conclusion that ICG-PDR may not accurately measure 
liver dysfunction in sepsis due to complex ICG kinetics 
in liver disease and temporary redistribution into extra-
hepatic-extravascular tissues [20]. Moreover, ICG elimi-
nation seems to be severely influenced by the splanchnic 
perfusion and is inhibited by hyperbilirubinemia, other 
anionic substances and acute cholestasis without evi-
dence of changes in hemodynamic or morphology of 
hepatocytes [21–24]. In addition, a recent study inves-
tigating liver function in sepsis showed a superiority of 
the LiMAx against the ICG-PDR in terms of quantifying 
liver dysfunction in critically ill patients [10]. Such find-
ings lead to the conclusion not to use the ICG-PDR in the 
recent study.
Static liver function parameters, such as AST, ALT, 
and GGT, failed to predict the degree of liver dysfunc-
tion accurately [25]. The results in the present study con-
firmed these findings. Since the values of lactate, INR, 
platelet count and ALP differed significantly between 
groups A and C, these parameters failed to predict the 
variability of TGC Cmax in the multivariate analysis. 
These findings are consistent with several studies, which 
identified only total bilirubin as a significant covariate to 
describe liver function [26–28]. Other authors concluded 
that INR is a reliable diagnostic tool to define liver failure 
[29]. INR can be influenced by disseminated intravascular 
coagulation or secondary hemorrhages, which are com-
mon complications in critically ill patients. A previous 
study in patients after major abdominal surgery showed 
similar postoperative progress of INR readouts compared 
with LiMAx values, while total bilirubin failed in pre-
dicting liver failure [15]. These heterogeneous results of 
different studies investigating the accuracy of static liver 
function parameters in defining liver function, point out 
weak reliability of these parameters in this specific issue.
Besides the described dynamic and static liver func-
tion tests, other tools are introduced to define liver fail-
ure. Korth-Bradley et al. described a significant increase 
in TGC Cmax and AUC in patients with advanced liver 
cirrhosis. The diagnostic tool used to define the degree 
of liver cirrhosis was the Child–Pugh score [30]. How-
ever, the Child–Pugh score in critically ill patients 
may not be suitable to describe liver dysfunction reli-
ably [31]. In a systematic review, Cholongitas et  al. 
mentioned that the Child–Pugh score in ICU patients 
can respond rapidly under treatment, resulting in an 
increase from class C to A. This apparent accelerated 
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improvement might result in adjusting antibiotic dos-
age unnecessarily with the possible consequence of 
overdosing and side effects [32]. Hence, guiding antibi-
otic therapy according to the Child–Pugh score in criti-
cally ill patients appears to be imprecise [33]. Based on 
these data, we decided not to use the Child–Pugh score 
in the present study.
Another tool targeting liver failure is the MELD 
score. Initially, the MELD score was evaluated for 
patients undergoing a transjugular intrahepatic porto-
systemic shunt [34]. The current version includes three 
objective variables (total bilirubin, INR and creatinine) 
and is simple to assess. The MELD score is predomi-
nantly used to prioritize the receipt of a liver transplant. 
Recent studies evaluated the MELD score in different 
clinical situations with positive results in patients with 
heart failure [35]. In the present study, the MELD score 
revealed no differences between groups A and C, and 
the multivariate analysis showed no significant impact 
of the MELD score on TGC Cmax. Hence, the MELD 
score appears not to be a reliable diagnostic tool to 
quantify liver dysfunction in critically ill patients.
In the present study, BMI was one parameter show-
ing promising differences between the study groups 
at baseline. Patients of group A (high Cmax) revealed a 
significantly lower mean BMI (26.4  kg/m2) compared 
to patients of group C (low Cmax, BMI 31.3 kg/m2). The 
low protein binding and high distribution of TGC may 
be one possible explanation of this effect. However, 
in the multivariate analysis, BMI failed to qualify as a 
predictor of TGC variability. These findings are in con-
cert with the results of other authors. Xie et  al. found 
in their study, that BMI was an important parameter 
influencing the total CL of TGC. The authors pointed 
out that in their model building process, the simula-
tions were beyond the BMI of the patients included 
and should be considered cautiously [36]. On the other 
hand, Pai et al. characterized the concentration profiles 
of TGC in the serum and urine of obese and normal-
weight healthy adults and found no differences [37]. 
In accordance with these data, BMI may provide as 
one parameter influencing TGC PK, but the exclusive 
impact on TGC distribution appears weak.
Conclusion
The results of this study indicate that TGC plasma lev-
els show wide variability in critically ill surgical patients. 
Since TGC is eliminated predominantly non-renal, liver 
dysfunction may be a critical reason for TGC variability. 
The correlation with the results of the LiMAx test con-
firms these findings and LiMAx may provide an adequate 
tool to determine the impact of liver dysfunction on the 
PK of TGC. LiMAx in combination with other diagnostic 
tools determining organ failure in critically ill people may 
enhance the individual dosage of anti-infective drugs, 
resulting in a better outcome for the patients.
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